Central to FL CARES’ innovative approach is the newly unveiled Platform for Accelerating Collaborative Computational Cancer Research, or PAC3R. This cutting-edge digital infrastructure serves as a sophisticated, secure environment for scientists to integrate, analyze, and disseminate vast troves of cancer-related data. What sets PAC3R apart is its adherence to the FAIR data principles—ensuring that data is findable, accessible, interoperable, and reusable—thereby breaking down traditional silos and accelerating hypothesis generation and validation across multidisciplinary teams.

The conceptual and practical architecture of PAC3R draws heavily from the previously launched Sylvester Data Portal, a comprehensive cloud-based ecosystem that amalgamates genomic sequences, pharmacological response profiles, treatment efficacy metrics, and potential drug-drug interaction data into a unified, interoperable resource. This integration not only facilitates unparalleled clinical and translational insights but also empowers computational oncology efforts aimed at unveiling novel therapeutic targets and resistance mechanisms with unprecedented scale and precision.

Importantly, PAC3R extends its collaborative reach beyond Sylvester, aggregating data contributions from a consortium of prominent institutions including Moffitt Cancer Center, Florida International University, Nova Southeastern University, University of North Florida, University of Florida Health Cancer Center, and the Herbert Wertheim University of Florida Scripps Institute for Biomedical Innovation & Technology. This expansive network dramatically broadens the breadth and diversity of data, capturing genetic and phenotypic variabilities across Florida’s richly diverse populations, which represent a unique microcosm for studying health disparities in cancer outcomes.

Beyond state boundaries, PAC3R integrates pivotal national datasets such as The Cancer Genome Atlas (TCGA) Project and the Clinical Proteomic Tumor Analysis Consortium (CPTAC), thereby leveraging comprehensive genomic and proteomic landscapes. These integrations fuel computational models that correlate molecular aberrations with clinical phenotypes and therapeutic response patterns. As a result, researchers can dissect cancer heterogeneity at multiple biological scales, driving precision oncology initiatives tailored to individual patient profiles.

At the forefront of this transformative initiative is Dr. Stephan C. Schürer, Associate Director of Data Science at Sylvester, who underscores the platform’s remarkable scale and utility. PAC3R currently hosts over 6.7 million carefully curated drug response signatures and bioactivity data points encompassing more than 30,000 molecular entities and upwards of 200 cancer cell lines. This extensive dataset not only enables high-throughput in silico screening for promising drug candidates but also supports the refinement of computational classifiers predictive of treatment efficacy and toxicity.

The PAC3R platform embodies a paradigm shift in cancer research, moving from isolated experimental studies toward a dynamic, data-centric ecosystem fostering continuous collaboration. By providing standardized computational tools and interoperable datasets, it empowers investigators to perform integrative analyses that transcend traditional disciplinary boundaries. These capabilities are pivotal to unraveling complex cancer biology, understanding differential drug responses, and ultimately improving clinical outcomes through data-driven precision medicine.

Such a federated approach also addresses the urgent need to comprehend cancer disparities rooted in genetic, socioeconomic, and environmental factors. By harmonizing datasets from diverse cohorts, FL CARES and PAC3R facilitate the identification of molecular drivers and resistance mechanisms specific to underrepresented populations, which historically have been excluded or underrepresented in clinical studies. This fosters more inclusive research agendas and equitable therapeutic discoveries.

The launch of this statewide network and its computational platform will be formally highlighted at the upcoming American Association for Cancer Research (AACR) Annual Meeting, held April 17-22, 2026. Here, experts from Sylvester and partner institutions will showcase how the integration of clinical and research data through PAC3R is redefining the landscape of cancer research infrastructure. The presentation promises to elucidate the technical foundations, data governance policies, and early scientific insights emerging from this collaborative ecosystem.

Technologically, the PAC3R platform employs cloud computing architectures optimized for secure data storage, high-throughput analytical workflows, and scalable machine learning pipelines. These features ensure robust privacy compliance alongside rapid computational turnaround times, enabling real-time hypothesis testing and iterative model refinement. The platform’s design also supports federated learning methods allowing cross-institutional model training without direct data sharing, which is crucial for maintaining patient confidentiality.

Looking ahead, the synergistic capabilities of FL CARES and PAC3R have the potential to catalyze a new era of computational oncology where multi-omics data harmonization and AI-driven analytics converge. Such integration can illuminate previously hidden molecular signatures, refine predictive biomarkers, and accelerate the translation of preclinical findings to clinical interventions. This paradigm not only enhances scientific discovery but also expedites the development of more effective, less toxic cancer therapies.

Sylvester Comprehensive Cancer Center continues to champion this initiative as a model for oncological collaboration, public health impact, and technological innovation. By orchestrating a statewide network that harnesses big data, computational power, and diverse expertise, FL CARES stands at the nexus of a transformative movement poised to dismantle longstanding barriers in cancer research and care. Ultimately, the platform’s success will empower researchers, clinicians, and patients alike, marking a substantial leap toward personalized, equitable cancer treatment strategies.

For more detailed insights on Sylvester’s pioneering efforts, interested readers can explore the InventUM blog and follow @SylvesterCancer on X for up-to-the-minute updates on research advancements and clinical care innovations emerging from this vibrant community.

Subject of Research: Cancer research, computational oncology, cancer genomics, data integration, cancer health disparities

Article Title: Revolutionizing Cancer Research: Florida’s FL CARES Network and the PAC3R Data Platform Unveil New Frontiers in Precision Oncology

News Publication Date: April 17, 2026

Web References:

• Sylvester Comprehensive Cancer Center: https://umiamihealth.org/en/sylvester-comprehensive-cancer-center
• Florida Cancer Research (FL CARES) Network: https://floridacancernetwork.org/
• Platform for Accelerating Collaborative Computational Cancer Research (PAC3R): https://pac3r.floridacancernetwork.org/
• The Cancer Genome Atlas Project: https://www.cancer.gov/ccg/research/genome-sequencing/tcga
• Clinical Proteomic Tumor Analysis Consortium (CPTAC): https://gdc.cancer.gov/about-gdc/contributed-genomic-data-cancer-research/clinical-proteomic-tumor-analysis-consortium-cptac
• AACR Annual Meeting 2026: https://www.aacr.org/meeting/aacr-annual-meeting-2026/

Keywords: Cancer research, computational biology, data sharing, precision medicine, cancer genomics, big data, health disparities, PAC3R, FL CARES, data platforms, bioinformatics, oncology collaboration

Since its inception, the Allison Institute has strategically recruited top-tier scientists whose work spans immunotherapy resistance, cancer vaccines, cellular and protein engineering, and tumor evolution. The newly appointed members represent a broad spectrum of research foci that address some of the most pressing challenges in oncology. By leveraging innovative methodologies such as chromatin remodeling analysis, mRNA delivery systems, and molecular glue technologies, these researchers aim to dissect the molecular and cellular underpinnings that govern immune evasion and therapeutic resistance in cancer.

Eric Gardner, joining as an assistant member, comes from Weill Cornell Medicine to lead research in the Thoracic/Head & Neck Medical Oncology division. His work delves into the dynamic processes of tumor evolution and plasticity, particularly in lung cancer, where tumor cells adapt to evade immune surveillance. Gardner’s lab examines how alterations in tumor cell state, through mechanisms like chromatin remodeling and lineage plasticity, contribute to the emergence of immunotherapy resistance. Understanding these adaptive processes is critical to developing strategies that sustain durable immune control over malignancies, a central goal of the Allison Institute’s resistance-focused research efforts.

Betty Kim, a core member and professor of Neurosurgery at MD Anderson, brings a focused expertise on brain tumors, specifically glioblastoma, one of the most aggressive and treatment-resistant cancers. Her laboratory harnesses avant-garde technologies including mRNA-loaded extracellular vesicles and nano-enabled delivery platforms to modulate antitumor immune responses within the central nervous system. Kim’s work sits at the intersection of cancer immunology and neuro-oncology, seeking not just to understand tumor immunodynamics but to pioneer innovative therapeutic avenues that can penetrate the blood-brain barrier and reprogram immune activity in the tumor microenvironment.

Rodrigo Romero, also joining as an assistant member from Memorial Sloan Kettering Cancer Center, investigates tumor lineage plasticity and its impact on disease progression in prostate cancer. His research emphasizes the use of engineered model systems to decode how a constellation of genetic and epigenetic factors — including tumor suppressor gene loss, chromatin modulation, and microenvironmental cues — enables tumor cells to transit between phenotypic states that evade both targeted and immune therapies. Romero’s investigations provide vital insights into the interplay between tumor evolution and immunotherapeutic efficacy, fostering novel approaches that could mitigate resistance in prostate and other cancers.

Hojong Yoon, who joined the Allison Institute in 2025 as an assistant member, is an expert in intracellular signaling pathways that orchestrate immune cell functions within the tumor milieu. Transplanted from the Broad Institute

Hepatocellular carcinoma ranks among the most fatal malignancies worldwide, often diagnosed at advanced stages where surgical options become nonviable. Immunotherapies, particularly immune checkpoint inhibitors like pembrolizumab, have ushered in new hope. When combined with lenvatinib, a multi-kinase inhibitor, patients exhibit improved outcomes, yet variability in response remains an unresolved clinical conundrum. Until now, the ability to forecast which individuals will benefit from such dual treatment regimens has been limited.

To confront this dilemma, a multidisciplinary team prospectively enrolled 51 patients with unresectable hepatocellular carcinoma between mid-2019 and mid-2023. Prior to initiating pembrolizumab-lenvatinib (PL) therapy, comprehensive peripheral blood samples were taken to map immune cell constituents in unprecedented detail. The team then meticulously monitored tumor response following RECIST 1.1 criteria to objectively stratify participants into responders and non-responders.

Intriguingly, 16 patients demonstrated objective tumor response, signaling significant reduction or stabilization of their disease, while 11 exhibited clear signs of tumor progression despite therapy. Detailed immunophenotyping revealed that responders possessed markedly elevated levels of total T cells and specifically CD8+ cytotoxic T cells, which are instrumental in targeting and eradicating malignant cells. Moreover, these patients showed enriched populations of PD-1-expressing subsets within CD4 and CD8 T cells, as well as natural killer (NK) cells, indicative of an activated yet regulated immune milieu conducive to tumor suppression.

In stark contrast, non-responders displayed a peculiar predominance of PD-L1-positive monocytes—immune cells that can contribute to an immunosuppressive tumor microenvironment by dampening anti-tumor immune responses. This dichotomy underscores the complex interplay of immune activation and suppression within the tumor-host interface and suggests that the balance of these cell types significantly influences therapeutic efficacy.

Capitalizing on these findings, the investigators constructed a machine learning model fueled by baseline immune cell profile data. This artificial intelligence-powered system demonstrated astonishing predictive power, achieving perfect sensitivity—catching every patient who would respond to treatment—while maintaining reasonable specificity. Notably, CD8+ T cells, PD-1+ CD8 NK cells, and PD-L1+ monocytes emerged as critical variables steering the model’s classification outcomes.

Such a paradigm of harnessing machine learning to parse multidimensional immunological data exemplifies the future of oncology diagnostics. Beyond simple biomarker detection, these algorithms integrate complex datasets to unveil subtle yet clinically meaningful patterns, empowering clinicians to tailor therapy with unprecedented precision. Implementation in clinical settings could spare patients from ineffective treatments, reduce adverse events, and optimize resource allocation.

The study further validates the concept that immune phenotyping of peripheral blood, an accessible and minimally invasive procedure, can faithfully reflect tumor immune dynamics. This is a significant leap as tumor biopsies, often fraught with sampling challenges and patient risk, have traditionally been the mainstay for such insights. The ability to leverage blood-based immune signatures heralds a new era of real-time monitoring and adaptable therapy adjustment.

While the efficacy of pembrolizumab and lenvatinib has been documented, prior efforts to predict patient outcomes relied mostly on clinical indicators and tumor genomic markers with limited success. By contrast, this study’s focus on immune cell populations and their functional states, combined with computational analysis, offers a more granular and functional perspective, directly tied to the immune system’s capacity to counteract cancer.

Looking ahead, integrating this machine learning approach with other modalities such as imaging, genetic profiling, and cytokine analyses could further refine prediction models. In addition, expanding sample sizes and validating findings across diverse populations and cancer subtypes will be crucial steps toward widespread clinical adoption.

These insights also raise compelling biological questions regarding whether modulation of PD-L1+ monocytes or enhancement of PD-1+ T and NK cells could serve as therapeutic targets themselves. The immunological tug-of-war observed here hints at potential avenues for combination strategies that not only employ checkpoint inhibitors but also calibrate innate immune cell functions.

Moreover, the importance of CD8+ T cells and specific NK cell subsets aligns with a growing appreciation of cytotoxic lymphocytes as frontline warriors against tumors. Understanding factors that govern their abundance, exhaustion status, and functional competence will be vital for advancing immunotherapy.

In parallel, the study’s demonstration that peripheral blood immune profiling can successfully classify patients into clinically relevant response categories paves the way for predictive biomarkers that are both practical and highly informative. With further refinement, such tools could be seamlessly integrated into routine oncology practice, enabling a precision medicine approach truly tailored to individual immunobiology.

In conclusion, this collaborative research represents a landmark achievement in characterizing immune landscapes that dictate responsiveness to combination immunotherapy in hepatocellular carcinoma. By marrying detailed immunophenotyping with cutting-edge machine learning, it charts a promising path toward predictive diagnostics and personalized treatment paradigms for patients battling this formidable disease. The future of cancer care, illuminated by such innovations, holds promise not only for enhanced survival but also for improved quality of life.

Subject of Research: Immune profiling in unresectable hepatocellular carcinoma patients undergoing pembrolizumab and lenvatinib therapy.

Article Title: Characterizing immune profiles in hepatocellular carcinoma patients benefiting from pembrolizumab and lenvatinib using machine learning

Article References:
Lee, PC., Li, PY., Lee, CY. et al. Characterizing immune profiles in hepatocellular carcinoma patients benefiting from pembrolizumab and lenvatinib using machine learning. BMC Cancer 25, 1641 (2025). https://doi.org/10.1186/s12885-025-14945-9

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14945-9

Keywords: Hepatocellular carcinoma, pembrolizumab, lenvatinib, immune profiling, machine learning, immunotherapy, CD8 T cells, PD-1, PD-L1, natural killer cells, predictive biomarkers